abstract: @entity72986 (CFAs) are synthetized in situ by the transfer of a @entity845 group from @entity3874 to a double bond of @entity5031 chains of membrane phospholipids. This conversion, catalyzed by the @entity3795 synthase enzyme, occurs in many bacteria and is recognized to play a key role in the adaptation of bacteria in response to a drastic perturbation of the environment. The role of CFAs in the acid tolerance response was investigated in the lactic acid bacterium @entity7878 MG1363. A mutant of the @entity3795 gene was constructed by allelic exchange. The @entity3795 gene encoding the @entity3795 synthase was cloned and introduced into the mutant to obtain the @entity465 for homologous system studies. Data obtained by gas chromatography (GC) and GC-mass spectrometry (GC-MS) validated that the mutant could not produce @entity3795 . The @entity3795 levels in both the wild-type and complemented strains increased upon their entry to stationary phase, especially with acid-adapted cells or, more surprisingly, with @entity1068 -adapted cells. The results obtained by performing quantitative reverse transcription-PCR (qRT-PCR) experiments showed that transcription of the @entity3795 gene was highly induced by acidity (by 10-fold with cells grown at pH 5.0) and by @entity1068 (by 9-fold with cells grown with 6% @entity1068 ) in comparison with that in stationary phase. Cell viability experiments were performed after an acidic shock on the mutant strain, the wild-type strain, and the @entity465 , as a control. The higher viability level of the acid-adapted cells of the three strains after 3 h of shock proved that the cyclopropanation of @entity1474 is not essential for @entity26135 survival under acidic conditions. Moreover, fluorescence anisotropy data showed that @entity3795 itself could not maintain the membrane fluidity level, particularly with @entity1068 -grown cells.

title: Cyclopropanation of membrane @entity1474 is not essential to the acid stress response of @entity7878 subsp. XXXX .

answer: @entity26135 :: (1359,Species) :: ['cremoris']


abstract: OBJECTIVE: Although @entity1 with postnatal-onset @entity4242 (POM) generally have poor development, we speculated that better somatic growth would predict better development in these @entity1 . @entity1 AND METHODS: We followed 57 @entity1 with POM for an average of 4.2 years (13 @entity9670 , 14 dysgenetic, 6 with @entity6694 , 24 idiopathic) and calculated the developmental quotient (DQ) at each visit (DQ > 0.70 was considered normal). @entity168 scores ( @entity214 ) for measurements were analyzed using a repeated measures mixed-effects model to assess effect of weight, height, @entity135 ( @entity135 ), and age on DQ. Pearson's correlation was used to examine the independent influence of each variable on final DQ. RESULTS: Forty-four @entity1 (77%) had a low DQ (mean: 0.33), but 13 (23%) had a normal DQ (mean: 0.93), including 10 idiopathic and 3 @entity9670 . Mean @entity135 fell below -2 @entity214 in all before 1 year (destructive at 3.3 months, idiopathic low-DQ at 7.5 months, dysgenetic at 8.5 months, @entity6694 at 11 months, and idiopathic normal-DQ at 11.5 months). Mean weights and heights both fell below -2 @entity214 for all low-DQ groups but remained normal in both normal-DQ groups. Weight, height, and @entity135 were independent predictors of DQ (P < .0001). Final DQ correlated with weight (r = 0.27), height (r = 0.41), and @entity135 (r = 0.13). CONCLUSIONS: Most @entity1 with POM have poor later development. Whatever the cause of POM, @entity1 in whom postnatal body growth (weight, height, @entity135 ) is better sustained have more favorable development, and in one-quarter of such @entity1 (mostly idiopathic POM), final DQ is normal.

title: Postnatal-onset XXXX : pathogenesis, patterns of growth, and prediction of outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'PATIENTS', 'persons']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head circumference', 'HC']

entities_list: @entity9670 :: ('MESH:D065708', 'Disease') :: ['encephaloclastic']

entities_list: @entity6694 :: ('MESH:D015518', 'Disease') :: ['Rett syndrome']

entities_list: @entity4242 :: ('MESH:D008831', 'Disease') :: ['microcephaly']

answer: @entity4242 :: (MESH:D008831,Disease) :: ['microcephaly']


abstract: OBJECTIVE: To report the impact of hospital-wide interventions on @entity281 ( @entity281 ) rates in a 24-bed @entity130 -surgical intensive care unit. DESIGN: Data were gathered retrospectively from January 1, 2001, through June 30, 2009. Interventions to reduce @entity281 rates during this period included standardization of line insertion and maintenance processes, development of a mandatory education program incorporating practical line insertion simulation sessions, frequent audits, and intensive care unit staffing modifications. We used the   (2) test and analysis of variance to analyze the data where appropriate. SETTING: Urban tertiary referral center providing level I @entity130 services. @entity1 : Eight thousand four hundred eighty-one @entity130 -surgical intensive care unit admissions, of which 76% were owing to @entity130 . RESULTS: During this period, the incidence of @entity281 declined from 6.1 to 0.3 per 1000 line-days. No CLABSIs occurred for 8 of the last 10 quarters (January 2007 to June 2009). Internal jugular sites were associated with a higher @entity281 rate than subclavian sites (P  =  .03). The central line utilization ratio remained high for most of the study period. When compared with the 2006-2007 Centers for Disease Control and Prevention data, the @entity130 -surgical intensive care unit was at the 10th percentile in CLABSIs and at the 75th to 90th percentile in central line utilization ratios. CONCLUSIONS: The significant decline in the incidence of CLABSIs, which reflected the national trend, could be attributed to multiple interventions. The high central line utilization ratio compared with nationally available data represents a potential target for further improvement.

title: Trends in central line-associated bloodstream infections in a XXXX -surgical intensive care unit.

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['CLABSI', 'central line-associated bloodstream infection']

answer: @entity130 :: (MESH:D014947,Disease) :: ['trauma']


abstract: BACKGROUND: @entity17791 ( @entity17791 ) is a rare complication of infection with @entity3218 that can lead to obstruction of pulmonary and systemic vasculature and large airways, often resulting in significant morbidity and mortality. Medical therapy is ineffective, and surgical intervention is often not feasible. Stent implantation offers a potential treatment for @entity455 due to @entity17791 , but this has not been well studied. METHODS AND RESULTS: We conducted a retrospective review of all @entity1 undergoing cardiac catheterization for @entity17791 . Anatomic site of stenosis and hemodynamic information before and after intervention, as well as clinical presentation and follow-up data, were recorded. From 1996 to 2008, 58 @entity1 underwent cardiac catheterization for @entity17791 , with intervention performed in 40 (69%). A total of 77 stents were used to relieve 59 lesions (pulmonary artery=26, pulmonary vein=21, and superior vena cava=12). Significant reduction in pressure gradients (P<0.001) and increase in vessel caliber (P<0.001) were seen at all locations. Symptomatic recurrent stenosis requiring further intervention occurred in 11 @entity1 (28%). Median time to recurrence was 115 months. Thirty-two (87%) of 37 @entity1 for whom follow-up was available reported symptomatic improvement after stent placement. PROCEDURE: related complications occurred in 14 @entity1 (24%). Overall mortality was 19%, with the majority of @entity204 in @entity1 with bilateral disease. Among @entity1 with bilateral disease, intervention was associated with improved survival at 5 years. CONCLUSION: Percutaneous vascular stent implantation is an effective therapy for central @entity455 due to @entity17791 , providing significant relief of anatomic obstruction and sustained clinical improvement.

title: Percutaneous vascular stent implantation as treatment for central XXXX due to fibrosing mediastinitis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular obstruction']

entities_list: @entity17791 :: ('MESH:C536136', 'Disease') :: ['FM', 'Fibrosing Mediastinitis']

entities_list: @entity3218 :: ('5037', 'Species') :: ['Histoplasma capsulatum']

answer: @entity455 :: (MESH:D014652,Disease) :: ['vascular obstruction']


abstract: BACKGROUND: Good medical care results in long survival for @entity1 with @entity191 ( @entity191 ). However, little is known about the burden of @entity191 comorbidity and mortality in Japan. This is the first study to examine comorbid diseases of @entity191 decedents and extrapolate @entity191 @entity204 rates from multiple-cause coding mortality data for the total population of Japan. METHODS: Data for 4589 certified deaths due to @entity191 as the underlying cause of @entity204 (ICD-10 code: @entity72987 ) were obtained from the 2008 Japanese vital statistics. Of those, comorbidities listed in the @entity204 certificates of 477 randomly selected decedents were analyzed. All @entity74 mentioned on @entity204 certificates were counted and ranked in descending order of frequency. The @entity204 rates (per 100,000 population) from @entity191 were calculated using Japanese National Vital Statistics. The estimated rate of deaths with @entity191 was extrapolated using US @entity204 data from a multiple-cause coding system, as no such system is available in Japan, with adjustment for the difference in disease structure between countries. RESULTS: Average age at @entity204 was 80.9 years. The top 5 comorbid diseases ranked as contributory causes of @entity204 were @entity66 (4.0%), @entity303 (3.8%), @entity6 (3.6%), @entity5 (2.5%), and @entity299 (2.3%). Overall, the @entity204 rates from and with @entity191 were 3.6 and 5.8, respectively. CONCLUSIONS: Analysis restricted to data from the underlying-cause coding system underestimated the national burden of @entity191 comorbidity and mortality. Use of @entity204 certificates and multiple-cause mortality data complement the existing system.

title: How can the national burden of XXXX comorbidity and mortality be estimated for the Japanese population?

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular diseases']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant neoplasm']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['diseases or conditions']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart diseases']

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: BACKGROUND: Beriberi occurs in Vientiane, @entity4602 PDR, among breastfed @entity1 . @entity922 may be the tip of an iceberg with @entity72988 contributing to other illnesses. Thiamin treatment could improve outcome. METHODOLOGY/PRINCIPAL FINDINGS: A cohort of 778 sick @entity1 admitted during one year without clinical evidence of beriberi were studied prospectively and erythrocyte transketolase assays (ETK) performed. @entity72988 was defined both in terms of the activation coefficient (a>31%) and basal ETK activity <0.59 micromoles/min/gHb. Of the 778 @entity1 , median (range) age was 5 (0-12) months, 79.2% were breastfed, 5.1% had a>31% and 13.4 % basal ETK<0.59 micromoles/min/gHb. @entity1 >= 2 months old had a higher frequency of biochemical markers of @entity72988 . Mortality was 5.5% but, among @entity1 >= 2 months old, mortality was higher in those with basal ETK<0.59 micromoles/min/gHb (3/47, 6.4%) than in those with basal ETK>= 0.59 micromoles/min/gHb (1/146, 0.7%) (P=0.045, relative risk=9.32 (95%CI 0.99 to 87.5)). Multivariate regression analysis indicated that @entity1 age>= 2 months and fewer maternal years of schooling were independently associated with @entity1 basal ETK<0.59 micromoles/min/gHb. CONCLUSIONS/SIGNIFICANCE: Clinically unapparent @entity72988 is common among sick @entity1 (>= 2 months old) admitted to hospital in Vientiane. This may contribute to mortality and a low clinical threshold for providing thiamin to sick @entity1 may be needed.

title: Clinically unapparent XXXX in Vientiane, Laos.

entities_list: @entity1 :: ('9606', 'Species') :: ['infants', 'Infants', 'infant']

entities_list: @entity72988 :: ('MESH:D013832', 'Disease') :: ['subclinical thiamin deficiency', 'Biochemical thiamin deficiency', 'thiamin deficiency']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['Clinical disease']

answer: @entity72988 :: (MESH:D013832,Disease) :: ['infantile thiamin deficiency']


abstract: PURPOSE: To determine the genetic and genomic alterations underlying classic @entity6716 in Saudi Arabia, a region with social preference for consanguineous marriage. METHODS: Prospective study of consecutive @entity1 referred to a pediatric ophthalmologist in Saudi Arabia (2005-2009). All @entity1 had @entity6484 ( @entity6484 ) analysis (sequencing and multiplex ligation-dependent probe amplification analysis if sequencing was normal). If @entity6484 analysis was negative, the following were performed: candidate gene sequencing ( @entity17967 [ @entity17967 ], @entity20195 [ @entity20195 ], @entity12325 , subfamily B [ @entity4188 ], paired-like homeodomain transcription factor 3 [ @entity66503 ], and v-maf avian musculoaponeurotic @entity1492 oncogene homolog [MAF]) and molecular karyotyping by array competitive genomic hybridization (250K single nucleotide polymorphism (SNP) arrays). RESULTS: All 12 probands (4 months-25 years of age; four @entity1 and eight @entity1 ) had @entity231 and @entity2070 in addition to no grossly visible iris. Four cases were familial. All cases were products of consanguineous unions except for three, one of which was endogamous. Heterozygous @entity6484 mutations (including two novel mutations) were detectable in all but two cases, both of which were sporadic. In one of these two cases, the phenotype segregated with homozygosity for a previously-reported pathogenic missense @entity17967 variant ( @entity34337 ) when homozygosity for chromosome 11q24.2 deletion (chr11:125,001,547-125,215,177 [ @entity72989 ; @entity72990 ]) was also present. In the other, no genetic or genomic abnormalities were found. CONCLUSIONS: The classic @entity6716 phenotype in Saudi Arabia is typically caused by heterozygous @entity6484 mutations, even in the setting of enhanced homozygosity from recent shared parental ancestry. For @entity6484 -negative cases, interaction between missense variation in an anterior segment developmental gene and copy number variation elsewhere in the genome may be a potential mechanism for the phenotype.

title: Genetic and genomic analysis of classic XXXX in Saudi Arabia.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'boys', 'girls']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['lens opacity']

entities_list: @entity20195 :: ('5308', 'Gene') :: ['PITX2', 'paired-like homeodomain transcription factor 2']

entities_list: @entity1492 :: ('MESH:D005354', 'Disease') :: ['fibrosarcoma']

entities_list: @entity2070 :: ('MESH:C537858', 'Disease') :: ['foveal hypoplasia']

answer: @entity6716 :: (MESH:D015783,Disease) :: ['aniridia']


abstract: Since April 2009, a serious @entity281 has been rapidly spread across the world. These @entity281 are caused due to the novel @entity1707 origin @entity778 and hence these are commonly called as " @entity1707 Flu". This new virus is the reassortment of avian, @entity1 and @entity1707 influenza viruses and thus it has a unique genome composition. There are 16 different types of hemagglutinin (HA) and 9 different types of @entity689 (NA) that can be genetically and antigenetically differentiated. The first @entity11317 isolated from @entity1707 was of the H1N1 subtype and these viruses have been reported to cause @entity281 in @entity1707 in many countries. The outbreak of this virus has been transmitted from @entity1707 to @entity1 . This new reassorted (exchange of genes) virus which is the cause of 2009 pandemic @entity281 has the ability to spread from @entity1 to @entity1 . This spread of @entity281 should be brought to an end. In this study, a phylogenetic analysis of the nucleotide sequences of the RNA segments of @entity1 H1N1 viruses was carried using MEGA version 4.0 to demonstrate the route map of @entity281 to India. Phylogenetic analysis of the sequences from India, published in Influenza Virus Resource (a database that integrates information gathered from the Influenza Genome Sequencing Project of the @entity166 ( @entity166 ) and the genbank of the (NCBI)) was retrieved and used for the analysis. The results showed that the various segments of the Indian isolates clustered well with the sequences from American, Asian and European countries and thus indicating the transmission of viruses from these places to India.

title: Phylogenetic analysis of H1N1 sequences from pandemic XXXX during 2009 in India.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['influenza A (H1N1) virus']

entities_list: @entity689 :: ('4758', 'Gene') :: ['neuraminidase']

entities_list: @entity11317 :: ('11320', 'Species') :: ['influenza A virus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'pandemic infection', 'infections']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['NIAID', 'National Institute of Allergy and Infectious diseases']

answer: @entity281 :: (MESH:D007239,Disease) :: ['infections']


abstract: @entity3609 are @entity5 developing as an anomaly of the lymphatic channels. Most of them are discovered in @entity1 and are located mostly in the head and neck with no differences between sexes. Retroperitoneal locations are rare, clinical symptoms not specific and are discovered incidentally. We report the case of a 32-year-old female sex @entity1 with a @entity5 situated in the retroperitoneum, behind the pancreas, discovered by abdominal ultrasound during a diagnostic work-out for @entity293 and @entity101 . Anamnesis, physical examination and CT-scan could not indicate the nature of the cyst. The @entity5 had a shape of a butterfly, crossing the midline in front of the aorta and vena cava. A laparotomy was indicated and established the diagnosis of a @entity5409 based on its macroscopic appearance. The @entity5 was approached from its right side by a generous Kocher maneuver and then from the left by disinsertion of the Treitz ligament and elevating the pancreatic body and splenic vessels. It was completely removed. Postoperative course was uneventful. Histopathologic examination confirmed the diagnosis of benign @entity3609 . At 2 years of follow-up the @entity1 was free of recidive. CONCLUSIONS: @entity3609 are rarely seen in adults. Precise diagnosis is made at laparotomy, imagistic test give details about walls, content, relationship with the surrounding structures and major blood vessels. Complete surgical resection represents the treatment of choice avoiding recurrence.

title: XXXX - considerations upon a case.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patient']

entities_list: @entity3609 :: ('MESH:D018191', 'Disease') :: ['Cystic lymphangiomas', 'cystic lymphangioma', 'Retropancreatic cystic lymphangioma']

entities_list: @entity5409 :: ('MESH:D052177', 'Disease') :: ['cystic lymphagioma']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'benign tumors', 'cystic tumor']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary infection']

answer: @entity3609 :: (MESH:D018191,Disease) :: ['Retropancreatic cystic lymphangioma']


abstract: @entity4032 ( @entity4032 ) is carried out as an alternative treatment of @entity955 refractory to conservative measures. An increasingly recognized complication of @entity4032 is an @entity1727 ( @entity1727 ). Neurological manifestations usually dominate the presentation of an @entity1727 and result from @entity299 of thrombi, transgressed esophageal contents, or air. AEFs have been reported after @entity4032 in 52 @entity1 (23 @entity1 , age 35-76 years), described in 24 publications, so far. AEFs manifest clinically on the average 17 days (3-38 days) after ablation. Neurological manifestations include @entity64 (n = 30), @entity410 (n = 9), transitory-ischaemic attacks (n = 6), @entity772 (n = 6), or @entity146 (n = 5). Imaging studies of the cerebrum most frequently show multiple @entity64 or air @entity887 . The diagnosis is made upon thoracic computed tomography with contrast media. An act of swallowing, trans-esophageal echocardiography, gastroscopy, or esophageal stenting must be avoided not to enlarge the shunt. The only expedient therapy is surgical closure of the @entity292 , but even then, the prognosis is poor with a mortality of 71%. AEFs should be suspected if there is a history of @entity4032 followed by fever, @entity158 , postprandial @entity64 , @entity410 , @entity772 , or @entity911 with a latency of days to 5 weeks after ablation. Diagnostic work-up must avoid measures, which enlarge the @entity292 . Treatment is surgical exclusively.

title: Neurological manifestations of XXXX from left atrial ablation.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['embolic strokes', 'cerebral strokes']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric abnormalities']

entities_list: @entity1727 :: ('MESH:D004937', 'Disease') :: ['atrio-esophageal fistula', 'AEF']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism']

entities_list: @entity911 :: ('MESH:D003221', 'Disease') :: ['confusion']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac embolism']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['thoracic pain']

entities_list: @entity4032 :: ('MESH:D059446', 'Disease') :: ['Left atrial ablation', 'LAAB']

answer: @entity1727 :: (MESH:D004937,Disease) :: ['atrio-esophageal fistulas']


abstract: Recently, it was demonstrated that arteriogenesis is enhanced in @entity19 deficient in regulatory T cells ( @entity1961 (+) @entity3783 (+) @entity3744 (+) T cell), which can suppress effector T cell responses. The present study investigates the effects of these regulatory T cells on arteriogenesis in more detail by either specific expanding or depleting regulatory T cells. Hind limb @entity63 was induced by electro-coagulation of the femoral artery in @entity19 . @entity1619 cells were either expanded by injecting @entity19 with a complex of @entity2047 with the @entity2047 monoclonal antibody JES6-1, or depleted by anti- @entity3783 antibody or diphtheria toxin injections in DEREG @entity19 (depletion of regulatory T cells). Blood flow restoration was monitored using laser Doppler perfusion imaging. Collateral arteries were visualized by immunohistochemistry. @entity1619 cell expansion led to a moderate though significant suppression of blood flow restoration after @entity63 induction. Surprisingly, depletion of regulatory T cells resulted in minor increase on blood flow recovery. However, collateral and capillary densities in the post- @entity63 skeletal muscle were significantly increased in DEREG @entity19 depleted for regulatory T cells. The presence of regulatory T cells after @entity63 induction when analysed in non-depleted DEREG @entity19 could be demonstrated by green fluorescent protein staining only in lymph nodes in the @entity63 area, and not in the @entity63 muscle tissue. The current study demonstrates that, even under conditions of major changes in regulatory T cell content, the contribution of regulatory T cells to the regulation of the arteriogenic response is only moderate.

title: A limited role for regulatory T cells in post- XXXX neovascularization.

entities_list: @entity1619 :: ('MESH:D015458', 'Disease') :: ['Regulatory T']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemic']


abstract: BACKGROUND AND OBJECTIVE: Cardiopulmonary bypass (CPB) in the treatment of locally advanced @entity5 invaded heart or great vessels was not well underwent. The aim of this study is to report the results of these cases with locally advanced @entity5 which were completely resected under CPB in our hospital. METHODS: Four @entity1 with locally advanced @entity5 were operated under CPB. All @entity1 had stage IIIb disease (T4N0M0). Moderate @entity2332 CPB was used for all 4 cases. The CPB time was 79 min-155 min and aortic cross-clamp time was 57 min-126 min, respectively. RESULTS: There was no operative death in this series. CPB was smooth, and heart automatically rebeated in the 4 @entity1 . All the 4 @entity1 were discharged in 3 weeks. One @entity1 dead of @entity712 at 13 months after operation, one case dead of distant tumor @entity3 at 22 months after operation. The other two @entity1 have survived over 25 months and 11 months, respectively. CONCLUSIONS: CPB is helpful for completely removal of locally advanced @entity5 .

title: [Experiences of cardiopulmonary bypass in the treatment of locally advanced XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['pulmonary malignant tumors', 'pulmonary malignant tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['pulmonary malignant tumors']


abstract: OBJECTIVE: To investigate the minimally-invasive ablation of @entity1181 of the ethmoid sinuses endonasally. METHODS: A retrospective analysis was done in 19 @entity1 (15 male, 4 female, aged between 14 - 67, medium 37) diagnosed as @entity1181 of ethmoid sinuses hospitalized from April 2005 to October 2009. All @entity1 underwent sixteen-detector row computed tomography scan and 3D reconstruction preoperatively. All underwent operation with the help of navigation system and nasal endoscope. RESULTS: The @entity1181 in all 19 @entity1 was removed successfully with endoscope and navigation system. Two open procedures (1 through superciliary arch incision and 1 through labiogingival incision) were performed to assist the removal of the @entity5 , 17 @entity5 were removed under endoscopic and navigation guidance. In 5 @entity1 whose @entity1181 was localized or with the diameter no more than 2 cm, these @entity1181 were removed endonasally with the help of navigation system. The @entity1181 in 2 @entity1 was found to have narrow basilar part and relatively dissociative were removed from oral cavity after abscisin the basilar part. The @entity1181 in 12 @entity1 were found to have basilar part connected with ante-meso skull base, lamina papyracea, orbital apex, cranialis opticus, fossa orbitalis bone, these @entity1181 were removed using electric drill with the guidance of navigation system. All @entity1 were followed up from 8 to 64 months, and were asymptomatic (1 @entity1 who suffered from amblyopia had the symptom disappeared, 2 @entity1 suffered from prosopo-eminence, 1 @entity1 was asymptomatic and 1 @entity1 was feeling better). Two @entity1 underwent removal of crista galli, 1 of them suffered from @entity86 , and recovered after endoscopic repairing procedure and iodoform gauze packing and recovered 15 days later. Two @entity1 who underwent removal of crista galli suffered from anosmia and never recovered after 9 and 26 months follow-up. One @entity1 with @entity1181 suffered from repeated crusting and abnormal odor, and recovered after nasal flushing. CONCLUSIONS: Endoscopic ablation of @entity1181 of the ethmoid sinuses with the guidance of navigation system is an accurate, secure, minimally-invasive procedure. @entity1181 on median line and localized in ethmoid sinus is an indication of this operation. Preoperative CT scan is a safeguard for an accurate operation.

title: [Endoscopic removal of ethmoid XXXX under navigation guidance].

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative cerebro-spinal rhinorrhea']

entities_list: @entity1181 :: ('MESH:D010016', 'Disease') :: ['ethmoid osteoma', 'osteoma', 'enormous osteoma', 'osteomas', 'Osteomas']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity1181 :: (MESH:D010016,Disease) :: ['osteomas']


abstract: The maximum dosage of @entity1499 ( @entity1500 ) for treatment of @entity309 ( @entity309 ) formally approved in Japan is 8 mg/week. We intended to examine the efficacy and safety of @entity1500 at dosages over 8 mg/week in Japanese @entity309 @entity1 using the large Institute of Rheumatology, @entity309 (IORRA) cohort database. Among 9,122 @entity1 registered in the IORRA database from the October 2000 survey to the October 2007 survey, 5,201 @entity1 who had been treated with @entity1500 were selected. We attempted to overcome the drawbacks innate to nonrandomized studies by using longitudinal analyses and multifactorial logistic regression analyses. Cross-sectional analysis of data obtained from the October 2007 survey indicated that dosages of @entity1500 higher than 8 mg/week were used in 27.5% of @entity1 treated with @entity1500 . Longitudinal analyses based on data from three consecutive phases showed that final Disease Activity Score-28 (DAS28) values were significantly lower [n = 260, mean difference 0.563, 95% confidence interval (CI) 0.438-0.688, P < 2.2   10(-22), two-sided paired t test] than initial values when @entity1500 was increased from 8 mg/week or lower to over 8 mg/week. In addition, longitudinal analyses based on data from two consecutive phases indicated decreases in DAS28 values of 0.26    1.04 (n = 690, P = 6.78   10(-11), two-sided paired t test) when @entity1500 dosages were increased from 8 mg/week or lower to over 8 mg/week, compared with decreases of 0.07    0.89 (n = 2,125, P = 0.000307) when the dosage was maintained at 8 mg/week. The decreases in DAS28 values were significantly larger in the former than the latter (P = 2.27   10(-6), two-sided unpaired t test). Concerning safety of @entity1500 at dosages over 8 mg/week, we performed logistic regression analysis in which the objective variable was the existence or nonexistence of self-reported side-effects and the explanatory variable was the @entity1500 dosage in the former phase, with adjustments made for age, sex, body mass index (BMI), @entity134 administration, @entity1501 administration, concomitant @entity358 , and @entity8 . The results indicated that @entity1500 dosages over 8 mg/week did not have any association with either severe or severe + moderate side-effects. These data regarding both efficacy and safety of @entity1500 at dosages over 8 mg/week in Japanese @entity309 @entity1 would provide the basis for use of the drug at dosages currently not formally approved by the Japanese government.

title: Studies of the efficacy and safety of XXXX at dosages over 8 mg/week using the IORRA cohort database.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary diseases']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid Arthritis', 'rheumatoid arthritis', 'RA']

answer: @entity1499 :: (MESH:D008727,Chemical) :: ['methotrexate']


abstract: PURPOSE: Previous studies show that @entity3575 pectin nasal spray (FPNS) rapidly provides clinically meaningful @entity158 relief in the treatment of breakthrough @entity5 (BTCP). This study assessed the long-term tolerability, acceptability and consistency of effect of FPNS in @entity1 with BTCP. METHODS: @entity1 (new and rolled over from earlier controlled studies) with @entity5 experiencing one to four episodes per day of BTCP whilst taking >=  60 mg/day of @entity1286 (or equivalent) given orally for @entity5 entered an open-label 16-week safety study. Safety and tolerability were assessed by adverse events (AEs), adverse drug reactions (ADRs), withdrawal due to AEs and by nasal assessments. Acceptability assessments included ratings of overall satisfaction with each treated episode and ease of use and convenience of FPNS. Additional rescue medication and dose stability were used to evaluate the consistency of effect. RESULTS: Four hundred three @entity1 were included in the safety and intent-to-treat analysis (42,227 episodes), 356 entered the treatment phase and 110 completed 16 weeks. Overall, 24.6% of 403 @entity1 reported treatment-related treatment-emergent AEs that were generally mild/moderate and typical of opioids; 20 @entity1 discontinued treatment due to an AE (9 were ADRs). Nasal assessments revealed no clinically significant effects; 94% of FPNS-treated episodes required no additional rescue medication. More than 90% of @entity1 did not have to increase their dose during the study. @entity1 reported overall satisfaction with FPNS for 90.1% of episodes. At week 12, 96.9% of @entity1 were satisfied with the ease of use and 97.9% with the convenience of FPNS. CONCLUSIONS: FPNS was generally well tolerated and well accepted for the treatment of BTCP, and doses remained stable over the 4-month study period.

title: Long-term tolerability, efficacy and acceptability of @entity3575 pectin nasal spray for breakthrough XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer pain']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

entities_list: @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer pain']


abstract: PURPOSE: Previous studies show that @entity3575 pectin nasal spray (FPNS) rapidly provides clinically meaningful @entity158 relief in the treatment of breakthrough @entity5 (BTCP). This study assessed the long-term tolerability, acceptability and consistency of effect of FPNS in @entity1 with BTCP. METHODS: @entity1 (new and rolled over from earlier controlled studies) with @entity5 experiencing one to four episodes per day of BTCP whilst taking >=  60 mg/day of @entity1286 (or equivalent) given orally for @entity5 entered an open-label 16-week safety study. Safety and tolerability were assessed by adverse events (AEs), adverse drug reactions (ADRs), withdrawal due to AEs and by nasal assessments. Acceptability assessments included ratings of overall satisfaction with each treated episode and ease of use and convenience of FPNS. Additional rescue medication and dose stability were used to evaluate the consistency of effect. RESULTS: Four hundred three @entity1 were included in the safety and intent-to-treat analysis (42,227 episodes), 356 entered the treatment phase and 110 completed 16 weeks. Overall, 24.6% of 403 @entity1 reported treatment-related treatment-emergent AEs that were generally mild/moderate and typical of opioids; 20 @entity1 discontinued treatment due to an AE (9 were ADRs). Nasal assessments revealed no clinically significant effects; 94% of FPNS-treated episodes required no additional rescue medication. More than 90% of @entity1 did not have to increase their dose during the study. @entity1 reported overall satisfaction with FPNS for 90.1% of episodes. At week 12, 96.9% of @entity1 were satisfied with the ease of use and 97.9% with the convenience of FPNS. CONCLUSIONS: FPNS was generally well tolerated and well accepted for the treatment of BTCP, and doses remained stable over the 4-month study period.

title: Long-term tolerability, efficacy and acceptability of XXXX pectin nasal spray for breakthrough @entity5 .

answer: @entity3575 :: (MESH:D005283,Chemical) :: ['fentanyl']


abstract: Changes in the cellularity of various adipose tissues in growing @entity291 were analyzed. Fifty male @entity291 were slaughtered between 15 and 65% of mature weight. The whole adipose mass, separated by dissection, was divided into three parts: subcutaneous, intermuscular, and internal adipose tissues. Lipid content, cell size and distribution, as well as cell number of these three parts were determined. Adipose cells became 15 times greater from 15 to 65% mature weight, whereas total adipose cell number increased only 1.8-fold. However, a significant @entity1373 occurred near 45% mature weight. These results suggested a cell size regulation by @entity1373 . Over the whole period studied (15-65% mature weight), @entity1373 was far higher in subcutaneous adipose tissue than in other tissues. This is discussed as related to the higher relative growth of this tissue. In each fatty tissue, two identical development periods were observed. Each of them began by an increase in small-sized cells ( @entity1373 ) followed by the filling of these cells ( @entity1184 ). These two periods were particularly clear in the case of subcutaneous tissue, in which the second @entity1373 occurred slightly later than in other fatty tissues. So, in all respects, subcutaneous fatty tissue appears to develop later than other tissues studied.

title: Cellularity of XXXX adipose tissues: developmental changes from 15 to 65 percent mature weight.

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophy']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: @entity15539 belongs to the non-tuberculous or "atypical" mycobacteria. The reservoirs for these ubiquitous and slowly growing bacteria are both fresh water and salt water. In particular, aquaria should be considered as important source of hobby-related @entity281 especially of fingers, hands and forearms. Affected are both immunosuppressed @entity1 and @entity1 with an intact immune system. Distinctive are erythematous plaques and nodules with tendency for @entity5656 , crusting, and superficial ulcerations, sometimes as @entity281 . The histology shows non-caseation granulomas containing epithelioid cells and Langhans giant cells. Using the Ziehl Neelsen staining, typical acid-fast rods are not always detectable. The molecular biological detection of mycobacterial DNA using polymerase chain reaction represents the standard method of diagnosis. Cryotherapy is frequently used as first treatment. For the often long-term tuberculostatic therapy, @entity1215 , @entity3110 , and @entity4581 are the most used agents.

title: [Infections due to XXXX : a review].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity3110 :: ('MESH:D004977', 'Chemical') :: ['ethambutol']

entities_list: @entity5656 :: ('MESH:D017488', 'Disease') :: ['hyperkeratosis']

entities_list: @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['sporotrichoid lymphocutaneous infection', 'infections']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

entities_list: @entity15539 :: ('1781', 'Species') :: ['Mycobacterium marinum']

answer: @entity15539 :: (1781,Species) :: ['Mycobacterium marinum']


abstract: Symptoms management in @entity15 is an integral part of its care. Accurate assessment and addressing the different symptoms provides increased quality of life among @entity1 with @entity15 . @entity12280 may be identified as primary, secondary, or tertiary symptoms. Primary symptoms, such as @entity425 , @entity13937 , are directly related to @entity17 and @entity393 . Secondary symptoms, such as @entity293 as a result of urinary retention, are a result of the primary symptoms. Tertiary symptoms, such as @entity308 or social isolation, are a result of the social and psychological consequences of the disease. Common @entity12280 include @entity1295 and @entity425 ; decreased balance, @entity508 and gait problems; @entity308 and cognitive issues; bladder, bowel, and @entity227 ; and @entity9 . Less-common symptoms include @entity4653 and @entity1282 , vertigo, and @entity400 . Rare symptoms in @entity15 include @entity410 , @entity393 , and @entity912 . Symptom management includes nonpharmacological methods, such as rehabilitation and psychosocial support, and pharmacological methods, ie, medications and surgical procedures. The keys to symptom management are awareness, knowledge, and coordination of care. Symptoms have to be recognized and management needs to be individualized. @entity15 therapeutics include nonpharmacological strategies that consist of lifestyle modifications, rehabilitation, social support, counseling, and pharmacological agents or surgical procedures. The goal is vigilant management to improve quality of life and promote realistic expectations and hope.

title: Therapeutics for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity13937 :: ('MESH:C535295', 'Disease') :: ['sensory loss, and ataxia']

entities_list: @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelination']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['reactive depression', 'depression']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['sexual deficits; visual and sensory loss']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity912 :: ('MESH:D010243', 'Disease') :: ['paralysis']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity12280 :: ('MESH:C566813', 'Disease') :: ['multiple sclerosis symptoms', 'Multiple sclerosis symptoms']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['axonal loss', 'hearing loss']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['Multiple sclerosis', 'multiple sclerosis']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infections']

entities_list: @entity4653 :: ('MESH:D004401', 'Disease') :: ['dysarthria']

answer: @entity12280 :: (MESH:C566813,Disease) :: ['multiple sclerosis symptoms']


abstract: BACKGROUND: To present our experience with Laparo-Endoscopic Single Site (LESS) management of @entity8 . MATERIAL AND METHOD: Between September 2008 and November 2009, 18 @entity1 underwent single port transumbilical laparoscopic surgery for nephrectomy for a nonfunctioning kidney (7 cases), cyst decortications for symptomatic @entity8 (10 cases), and redo-dismembered pyeloplasty with previously failed laparoscopic surgical repair (1 case). @entity1 underwent surgery through a single 2-cm infraumbilical incision with the triport laparoscopic-port. All pathological reports of LESS nephrectomy and cyst decortications confirmed with chronic @entity2885 and simple cysts, respectively Histology of xanthogranulomotus @entity2885 showed two cases of the nephrectomy procedure. RESULTS: Mean @entity1 age and BMI were 61 +/- SD 14.2 years and 24.75 +/- SD 11.2 kg/m2, respectively Mean operating time was 187.7 +/- SD 71.4 min. LESS was a possible and safe approach in 77.8% of @entity1 . All LESS cyst decortications and redo-pyeloplasty were completed without major complications or conversion to open surgery. However, there was one case each of LESS cyst decortication and pyeloplasty requiring an additional 3-mm port for suturing due to @entity548 and an instrument error. For LESS nephrectomy, two (28.6%) with higher waist circumference were converted to standard laparoscopic nephrectomy due to failure to progress. One post operative complication of incisional @entity547 occurred in a @entity1 with chronic @entity3617 and @entity565 . CONCLUSION: LESS for the management of @entity8 is an effective and safe treatment option with selected @entity1 and experienced surgeon.

title: Laparo-endoscopic single site (LESS) management of XXXX : evaluation of complications.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal cyst', 'benign kidney diseases']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['pyelonephritis']

answer: @entity8 :: (MESH:D007674,Disease) :: ['benign kidney diseases']


abstract: BACKGROUND: Tightening and contracture of the joint capsule are hallmarks of @entity2585 of the shoulder (ACS). However, quantification of capsular stiffness and its relation to clinical features have not been investigated thoroughly. OBJECTIVES: To quantify capsular stiffness during @entity7334 ( @entity7334 ) and to investigate its relationships with @entity158 severity, symptom duration, range of motion (ROM), gender, and @entity6 status. DESIGN: Case series. SETTING: University outpatient clinic of physical medicine and rehabilitation. @entity1 : A total of 107 consecutive @entity1 with ACS who underwent @entity7334 . METHODS: Pressure-volume monitoring data during @entity7334 , @entity158 severity, symptom duration, shoulder ROM, and @entity6 status were obtained by retrospective chart review. Capsular stiffness ( @entity69674 ) was measured by calculating the slope of the elastic phase in pressure-volume curves. ROM was evaluated in 3 directions (flexion, abduction, and external rotation) with a goniometer, and the sum of the 3 ROMs was calculated. MAIN OUTCOME MEASUREMENTS: Pearson correlation coefficients and comparisons of averages were used to analyze the relationships between @entity69674 and clinical features. RESULTS: The mean @entity69674 of the total group of @entity1 was 26.0    14.2 mmHg/mL. Shoulder @entity158 in motion or rest did not correlate with @entity69674 . @entity1 with stiffer capsules had smaller sums of ROMs (r = -.298, P = .002), with distinct limitations in external rotation and abduction (r = -.278, P = .004 and r = -.313, P = .001, respectively). @entity1 had significantly stiffer capsules than @entity1 (29.5    14.3 versus 20.2    12.1 mmHg/mL, P = .001). @entity6 status had no significant effect on capsular stiffness. CONCLUSIONS: Capsular stiffness of the glenohumeral joint significantly correlated with limitation in shoulder ROM, especially in the abduction and external rotation directions, whereas there were no meaningful relationships with @entity158 during motion or rest. This is the first study to reveal the relationships between in  vivo quantified capsular stiffness and shoulder ROM limitations.

title: Relationships Between Capsular Stiffness and Clinical Features in XXXX of the Shoulder.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'Women', 'PARTICIPANTS', 'men']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity2585 :: ('MESH:D002062', 'Disease') :: ['adhesive capsulitis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'shoulder pain']

entities_list: @entity7334 :: ('MESH:D057072', 'Disease') :: ['intra-articular hydraulic distension', 'IHD']

answer: @entity2585 :: (MESH:D002062,Disease) :: ['Adhesive Capsulitis']


abstract: INTRODUCTION: Up to 50% of adults with @entity712 ( @entity712 ) and left @entity67 demonstrate Cheyne-Stokes respiration (CSR), although the mechanisms remain controversial. Because CSR has been minimally studied in @entity1 , we sought to assess the prevalence of CSR in @entity1 with low and high output @entity712 . We hypothesized that the existence of CSR only in @entity1 with low output @entity712 would support the importance of circulatory delay as a CSR mechanism. METHODS: Thirty @entity1 participated: 10 @entity1 with @entity712 , 10 matched @entity1 with no @entity299 , and 10 adults with @entity712 . All @entity1 underwent an in-laboratory polysomnographic sleep study. RESULTS: @entity712 @entity1 's average age (  SEM) was 3.6        2.1 years vs. 3.7        2 years in the age-matched control group. The average ejection fraction of three @entity1 with low output @entity712 was 22        6.8%. The remaining seven had normal-high cardiac output. Compared to control @entity1 , @entity712 @entity1 were tachypneic and tachycardic during stable sleep (55.1        6.7 vs. 26.9        3 breath/min and 127.6        8.7 vs. 97.6        6.9 beats/min, respectively, p   <   0.05 for both). They had shorter total sleep time (195        49 vs. 373        16 min, p   <   0.05) with a low sleep efficiency of 65.6        6%. None of the @entity1 had a pattern of CSR at any time during the studies while the adults with @entity712 had 40% prevalence of CSR. CONCLUSIONS: The complete absence of CSR in our sample of @entity1 with @entity712 compared to the 40% prevalence in the adults with @entity712 we studied, suggests that CSR may be an age-dependent phenomenon. Thus, we speculate that regardless of the exact mechanism which drives CSR, age is an over-riding factor.

title: The occurrence of cheyne-stokes respiration in XXXX : the effect of age.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children', 'patients']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysfunction']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'cardiac failure', 'CHF']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

answer: @entity712 :: (MESH:D006333,Disease) :: ['congestive heart failure']


abstract: @entity2348 in myocardium may lead to the @entity296 , which may progress to @entity384 and @entity1167 . @entity796 has been reported to cause @entity2401 and other @entity281 especially in immunocompromised @entity1 . To understand the cellular responses during the establishment of @entity281 in myocardium, we challenged differentiated H9C2 cells with @entity5175 . We also did comparison studies with infected undifferentiated form of H9C2 cells. Invasion studies revealed that @entity5175 can invade both forms of cells and is able to survive and replicate within the host. Internalization of @entity5175 was confirmed by live cell imaging and flow cytometry analysis. Though invasion of the pathogen triggered an increased ROS production in the host cells at earlier post- @entity281 periods, it was decreased at later post- @entity281 periods. Invasion of @entity5175 induced cell @entity204 through apoptosis in differentiated H9C2 cells. Significant decrease in cell size, formation of polarized mitochondria, and nuclear fragmentation were observed in the infected differentiated cells. On the contrary, cell @entity204 preceded by multinucleation was observed in infected undifferentiated H9C2 cells. Morphological markers such as multinuclei and micro nuclei were observed. Cell cycle arrest in G2/M phase corroborates that the undifferentiated H9C2 cells experienced cell @entity204 preceded by multinucleation.

title: @entity5175 induces distinct cell XXXX mechanisms in H9C2 cells and its differentiated form.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial damage']

entities_list: @entity796 :: ('287', 'Species') :: ['Pseudomonas aeruginosa']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['dilated cardiomyopathy']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['Bacterial infections']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['systemic infections', 'infection']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity2401 :: ('MESH:D009205', 'Disease') :: ['myocarditis']

answer: @entity204 :: (MESH:D003643,Disease) :: ['death']


abstract: @entity2348 in myocardium may lead to the @entity296 , which may progress to @entity384 and @entity1167 . @entity796 has been reported to cause @entity2401 and other @entity281 especially in immunocompromised @entity1 . To understand the cellular responses during the establishment of @entity281 in myocardium, we challenged differentiated H9C2 cells with @entity5175 . We also did comparison studies with infected undifferentiated form of H9C2 cells. Invasion studies revealed that @entity5175 can invade both forms of cells and is able to survive and replicate within the host. Internalization of @entity5175 was confirmed by live cell imaging and flow cytometry analysis. Though invasion of the pathogen triggered an increased ROS production in the host cells at earlier post- @entity281 periods, it was decreased at later post- @entity281 periods. Invasion of @entity5175 induced cell @entity204 through apoptosis in differentiated H9C2 cells. Significant decrease in cell size, formation of polarized mitochondria, and nuclear fragmentation were observed in the infected differentiated cells. On the contrary, cell @entity204 preceded by multinucleation was observed in infected undifferentiated H9C2 cells. Morphological markers such as multinuclei and micro nuclei were observed. Cell cycle arrest in G2/M phase corroborates that the undifferentiated H9C2 cells experienced cell @entity204 preceded by multinucleation.

title: XXXX induces distinct cell @entity204 mechanisms in H9C2 cells and its differentiated form.

answer: @entity5175 :: (208964,Species) :: ['Pseudomonas aeruginosa PAO1']


abstract: PURPOSE: Currently, there are several @entity901 combination regimens for first-line therapy of metastatic @entity14 (mCRC). In this study, we compared the survival outcomes of mCRC @entity1 treated with bevacizumab in combination with either modified @entity1487 /FA/ @entity901 (mFOL- FOX6) or @entity416 / @entity901 (XELOX). METHODS: We designed a two-arm retrospective study of mCRC @entity1 with @entity694 who were treated with bevacizumab and either mFOLFOX6 or XELOX and who had complete clinical and treatment data. We analysed their therapeutic responses, adverse events, progression-free survival (PFS), and overall survival (OS), and then determined whether there were any statistically significant differences. RESULTS: A total of 131 @entity1 (85 male; 65% and 46 female; 35%) were evaluated. Fifty-seven @entity1 (43.5%) were treated with bevacizumab and mFOLFOX6 and 74 (56.5%) with bevacizumab and XELOX. The median PFS was 9.1 months (95% CI, 4.9-13.1) and 10 months (95% CI, 4.2-15.9) in the mFOLFOX6 and XELOX arms, respectively (p=0.610). The median OS was 29 months (95% CI, 21.6- 34.3) and 27.5 months (95% CI 20-38) in the mFOLFOX6 and XELOX arms (p=0.812), respectively. The most common reason for treatment withdrawal was disease progression (102 @entity1 ; 91%) and the most common grade 3-4 @entity137 was @entity16 ( <=14%). CONCLUSION: Our results show that XELOX is a safe and effective alternative to mFOLFOX6 when combined with bevacizumab as first-line treatment for mCRC @entity1 .

title: Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic XXXX .

entities_list: @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['adenocarcinoma of the colon or rectum']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: PURPOSE: To assess the efficacy and safety of using 3D conformal radiation therapy (3DCRT) to treat @entity5 ( @entity5 ) in a Caucasian cohort and evaluate factors with prognostic value. METHODS: Between September 2001 and November 2012, 44 @entity5 @entity1 with a mean age of 57 years underwent 3DCRT at the University Hospital of Ioannina. Nineteen @entity1 (43%) presented with WHO type 1 and 2 histology. Thirty two @entity1 (73%) had @entity5 (stage III/IV). Thirty-one @entity1 (70%) received chemotherapy. The mean total radiotherapy dose prescribed to the planning target volume ( @entity343 ) was 67.2 Gy. The daily dose was 1.8 Gy. RESULTS: With a median follow up of 43 months (range 8.4-125), the 4-year local relapse-free (LRFS), nodal relapse-free (NRFS), distant metastases-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) were 90, 87, 91, 80 and 82%, respectively. Histology was a significant prognostic factor concerning overall survival, with worst prognosis in @entity1 with WHO type 1/2 compared to type 3. Age <70 years, absence of retropharyngeal lymph node @entity3 , complete response after treatment and the completion of >= 4 cycles of concurrent weekly @entity900 favored overall survival. Fifteen @entity1 (34%) developed grade 3 late side effects ( @entity2133 : 6, soft tissue @entity82 : 6, @entity393 : 2, @entity11438 : 1). CONCLUSION: 3DCRT in our Caucasian cohort, characterized by predominantly @entity5 , combined with chemotherapy, is an effective treatment modality approach in @entity1 with @entity5 with excellent tolerance.

title: 3D conformal radiotherapy in primary XXXX : effectiveness and prognostic factors.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['NPC', 'nasopharyngeal cancer', 'advanced-stage disease']

entities_list: @entity2133 :: ('MESH:D014987', 'Disease') :: ['xerostomia']

entities_list: @entity11438 :: ('MESH:D020968', 'Disease') :: ['brachial plexus neuralgia']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

answer: @entity5 :: (MESH:D009369,Disease) :: ['nasopharyngeal cancer']


abstract: BACKGROUND: Various studies showed that chemotherapy can control @entity2040 morbidity, but association of measures (water supply, sewage disposal and increase of socioeconomic conditions) is necessary for transmission control. METHODOLOGY/PRINCIPAL FINDINGS: A survey dealing with socioeconomic conditions, snail survey, contact with natural waters, and clinical and stool examinations was undertaken at an endemic area in the State of Minas Gerais, Brazil. The methodology used was the same for both evaluations (1981 and 2005). Four hundred and seventy-five out of 1,474 individuals studied in 1981 could be contacted. From these, 358 were submitted to stool examination, and 231 of them were clinically examined. @entity1 eliminating @entity383 eggs in their stools were treated. The results showed that the prevalence rate in Comercinho, a municipality of the State of Minas Gerais, Brazil, was substantially reduced to 70.4% and 1.7% in 1981 and 2005, respectively, as well as the frequency of the hepatosplenic form (7% to 1.3%) after five treatments effectuated between 1981 and 1992. No other new case of this form was detected from 1981 onwards. Another important aspect to be considered was the improvement of @entity1 's living standard that occurred in the region after more than two decades' efforts (better housing, professional skill and adequate basic sanitation). CONCLUSION/SIGNIFICANCE: The control of morbidity and very significant decrease of @entity2040 transmission in an area until then considered as hyperendemic was possible by means of association of successive specific treatments of the local population, together with the construction of privies, water supply in the houses and improvement of socioeconomic conditions.

title: Evaluation of a 25-year-program for the control of XXXX mansoni in an endemic area in Brazil.

entities_list: @entity1 :: ('9606', 'Species') :: ['people', 'Patients']

entities_list: @entity2040 :: ('MESH:D012552', 'Disease') :: ['schistosomiasis']

answer: @entity2040 :: (MESH:D012552,Disease) :: ['schistosomiasis']


abstract: PURPOSE: To evaluate the effectiveness of reconstruction with a modular hemipelvic endoprosthesis after @entity530 resection. METHODS: We retrospectively studied 50 consecutive @entity1 diagnosed with @entity530 from 2003 to 2013. All @entity1 received limb-salvage surgery and reconstruction with modular hemipelvic endoprosthesis. RESULTS: @entity1 were followed for an average of 54 months. At the most recent follow-up, 32 @entity1 were alive with an estimated three-year and five-year survival rate of 66.3% and 57.5% according to the Kaplan-Meier survival analysis. Eighteen @entity1 died from the @entity5 , with a mean survival of 28 months, and 9 @entity1 experienced local recurrence at an average of 19.6 months after surgery. @entity1 with marginal or intracapsular surgical margins had a significantly higher recurrence rate than those with wide margins (p=0.02). @entity3 occurred in 12 cases at an average of 16 months after surgery. The perioperative complication rate was 48.0%, and the most common complications were wound healing disturbance (28.0%) and deep @entity281 (14.0%). The endoprosthetic complication rate was 16.0%, and breakage of the pubic connection plate was the most common complication. The mean Musculoskeletal Tumor Society score was 61.4%. CONCLUSION: Reconstruction with a modular hemipelvic endoprosthesis after @entity530 resection can improve function, with an acceptable complication rate.

title: Reconstruction with modular hemipelvic endoprosthesis after XXXX resection: a report of 50 consecutive cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity530 :: ('MESH:D010386', 'Disease') :: ['pelvic tumor']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastasis']

answer: @entity530 :: (MESH:D010386,Disease) :: ['pelvic tumor']


abstract: UNASSIGNED: This study was conducted at high altitude (2100  m above sea level). A total of 208 d-old male broilers (Ross 308) were randomised across 16 floor pens and reared up to 42 d. A normal-protein diet (NPD) was formulated according to the National Research Council. A @entity146 ( @entity146 ) was prepared with dietary protein reduced by 30  g/kg relative to that of the NPD. Two additional diets were prepared by adding 2 and 4  g  @entity8561 ( @entity534 )/kg to the @entity146 . At the end of trial (42 d), blood sampling was done and carcass characteristics were recorded. @entity534 supplementation of the @entity146 at 4  g improved feed:gain in the growing stage and throughout the trial compared with the @entity146 . The right-to-total ventricular weight ratio was significantly increased in birds fed on @entity146 compared with those fed on NPD or @entity534 -supplemented @entity146 . Feeding @entity146 caused a significant decrease in plasma concentrations of @entity842 (NO) and @entity414 . Plasma NO level, however, was restored by @entity534 supplementation of @entity146 . @entity534 supplementation of @entity146 , however, significantly reduced the rate of @entity120 syndrome mortality compared to the negative control fed on @entity146 .

title: XXXX supplementation of reduced-protein diets improves pulmonary hypertensive response in broiler chickens reared at high altitude.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['reduced-protein diet', 'RPD']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity8561 :: (D001120,Chemical) :: ['L-arginine']


abstract: UNASSIGNED: An expanded G4C2 repeat in @entity3301 represents the most common known genetic cause of @entity746 ( @entity746 ) and @entity747 ( @entity747 ). However, the lower limit for pathological expansions is unknown (the suggested cutoff is 30 repeats). It has been proposed that the expansion might have occurred only once in @entity1 history and subsequently spread throughout the population. However, our present findings support a hypothesis of multiple origins for the expansion. We report a British-Canadian family in whom a    70-repeat allele from the father (unaffected by @entity746 or @entity747 at age 89 years) expanded during parent-offspring transmission and started the first generation affected by @entity746 (four @entity1 carry an    1,750-repeat allele). Epigenetic and RNA-expression analyses further discriminated the offspring's large expansions (which were methylated and associated with reduced @entity3301 expression) from the    70-repeat allele (which was unmethylated and associated with upregulation of @entity3301 ). Moreover, RNA foci were only detected in fibroblasts from offspring with large expansions, but not in the father, who has the    70-repeat allele. All family members with expansions were found to have an ancient known risk haplotype, although it was inherited on a unique 5-Mb genetic backbone. We conclude that small expansions (e.g., 70 repeats) might be considered "pre-mutations" to reflect their propensity to expand in the next generation. Follow-up studies might help explain the high frequency of @entity746 - or @entity747 -affected individuals with an expansion but without a familial history (e.g., 21% among Finnish @entity746 subjects).

title: Jump from Pre-mutation to Pathologic Expansion in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'human']

entities_list: @entity747 :: ('MESH:D057174', 'Disease') :: ['frontotemporal lobar degeneration', 'FTLD']

entities_list: @entity746 :: ('MESH:D000690', 'Disease') :: ['ALS', 'amyotrophic lateral sclerosis']

answer: @entity3301 :: (203228,Gene) :: ['C9orf72']


abstract: Tipula iridescent virus (TIV) is a relatively large particle containing about 15% DNA. As shown elsewhere by X-ray microanalysis (Thomas RS, Corlett M: J Histochem Cytochem 29:394, 1981), low-temperature @entity26 plasma microincineration of the virus produces a stable @entity72991 ash representing this DNA nearly quantitatively. @entity1579 ( @entity1579 ) of entire particles after plasma incineration shows the ash confined to the viral cores, confirming the previously known general location of the nucleic acid. Examination of ultrathin-sectioned virus crystals after plasma etching or ashing shows, on a still finer scale, that the DNA is probably confined to a shell structure within the core. A fine trace of ash from the capsid, seen in some preparations, may represent a phospholipid internal membrane known to be present. The possibilities of ash pattern artifacts are discussed. Heating experiments show that the ash patterns (and native virus particles) evaporate completely at high temperature, consistent with their presumed @entity72992 composition. A heat-stable ash could be formed, however, when the viral DNA became accidentally stained with @entity68 from the steel @entity1579 grids used--a noteworthy artifact. The present work suggests some future possibilities of the plasma microincineration technique. In particular, the ability to see directly the fine distribution of mineral concentrations in ash patterns with the full resolution of @entity1579 should be a powerful adjunct to increase effectively the sensitivity and resolution of X-ray microanalysis of mineral constituents in biological specimens.

title: Localization of DNA phosphorus in Tipula iridescent virus by XXXX plasma microincineration. I. Electron microscopy of ash structures.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity1579 :: ('MESH:D017096', 'Disease') :: ['TEM', 'Transmission electron microscopy']

entities_list: @entity72991 :: ('CHEBI:37372', 'Chemical') :: ['phosphorus oxide']

entities_list: @entity72992 :: ('MESH:C047269', 'Chemical') :: ['polyphosphoric acid']

answer: @entity26 :: (MESH:D010100,Chemical) :: ['oxygen']


abstract: BACKGROUND: @entity8434 is a near-cosmopolitan zoonosis caused by adult or larval stages of tapeworms (cestodes) into the genus Echinococcus (family Taeniidae). It was demonstrated that platelets were capable of killing parasites independent from leukocytes. PURPOSE: The aim of our study was to examine mean platelet volume ( @entity6688 ), platelet mass (PM) and platelet count (PC), which are practical indicators of platelet activity in preoperative and postoperative periods of the @entity1 with hydatid cyst. METHODS: In this retrospective study we evaluated 72 @entity1 admitted to clinic of chest surgery with a diagnosis of pulmonary hydatid cyst in our hospital between January, 2006, and October, 2008. The @entity6688 , PC, and PM were evaluated by complete blood count. PM was calculated by multiplying @entity6688 and PLT. RESULTS: PREOPERATIVE @entity6688 VALUES OF THE @entity1 WAS FOUND TO BE SIGNIFICANTLY HIGHER THAN POSTOPERATIVE @entity6688 VALUES (MEAN: 8.07  0.83, 7.78  0.87, p= 0.002). Preoperative PM values (median: 2456.75, range: 1013.70-5046.60) was found to be higher when compared to postoperative PM values (median: 2280.80, range: 134.20-4042.60) (p= 0.039). PC values were not significantly different between two periods (Preoperative-postoperative PC mean values: 320.48  98.42, 307.29  96.45, p= 0.286). CONCLUSION: In this study, we demonstrated that there were no statistical difference in PC for both periods but, @entity6688 and PM were found statistical higher than postoperative period in preoperative period. PM and PM can be used as markers of disease activity in @entity1 who undergo surgical resection of hydatid cyst.

title: Evaluation of platelet parameters in XXXX with pulmonary hydatid cyst.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity8434 :: ('MESH:D004443', 'Disease') :: ['Echinococcosis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The long term follow up studies on cases of @entity65 during pregnancy or delivery were reviewed in 181 @entity1 administrated in our clinic. The results as follows: 1. An incidence of @entity1 with @entity65 during pregnancy was 1.46 per cent as a whole, and there was increasing tendency in @entity299 . 2. An @entity712 during pregnancy was seen in 7.7 per cent and all cases with NYHA III grade had an incidence of 100 per cent. 3. The occurrence of @entity8956 and @entity20831 pregnancy were more frequently seen in group of @entity299 than in controls. But, no difference was observed in spontaneous @entity1763 . 4. 28 @entity1 with Starr-Edwards prosthetic heart valves became pregnant in our clinic. In these pregnancies, 5 cases receiving with @entity1229 therapy resulted in 3 anomalies of new born and in 2 spontaneous @entity5852 . So, the use of @entity1229 seemed to have the risk to the fetus. But omission of the anticoagulant therapy on the other hand, increased the danger of systemic embolization to the mother. 5. The follow up study by mail in some cases revealed that, as a general, pregnancy and delivery may aggravate the condition of @entity1 , especially who had mitral @entity712 .

title: [Clinical studies on cases of XXXX during pregnancy (author's transl)].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failures', 'accidental heart failure']

entities_list: @entity1763 :: ('MESH:D001237', 'Disease') :: ['abortion or neonatal asphyxia']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease', 'congenital heart disease']

entities_list: @entity8956 :: ('MESH:C565846', 'Disease') :: ['toxicosis']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease', 'cardiovascular diseases']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

answer: @entity65 :: (MESH:D002318,Disease) :: ['cardiovascular disease']


abstract: The histogenesis of @entity530 can not be sufficiently accounted for by a single theory. Thus it may be necessary to pressure plural theories for the explanation of their histogenesis. On collected 253 cases of @entity46 , some clinical and pathological studies were carried out and classified to @entity1870 (A) 37%, @entity43 ( @entity43 ) 17%, and others (A+ @entity43 ) 45%. Age of the group @entity43 @entity1870 (A) 37%, @entity43 ( @entity43 ) 17%, and others (A+ @entity43 ) 45%. Age of the group @entity43 tended to be younger, as compared with other groups. Pathological study revealed that in group (A+ @entity43 ), the lesion tended to be younger, as compared with other groups. Pathological study revealed that in group (A+ @entity43 ), the lesion in uterine wall was extensive and deep proliferation in many cases, and it was frequently more at least than group A. Especially, it is necessary to distinguish from each other two different cases which showed @entity43 , that is, to distinguish them by the presence or absence of @entity1870 . In the case of group @entity43 complicated by A, it is thought highly probable that discrete dissemination may take place from the foci of @entity1870 . In the case of group @entity43 there may be sufficient room for the application of the Sampson's theory or metaplastic theories. In view of conspicuous trait in the age, however, the possibility of lymphogenous dissemination of @entity46 may be valuable.

title: Study on histogenesis of XXXX .

entities_list: @entity530 :: ('MESH:D010386', 'Disease') :: ['pelvic endometriosis']

entities_list: @entity1870 :: ('MESH:D062788', 'Disease') :: ['adenomyosis']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['endometriosis in the ovary and pelvic peritoneum', 'ovarian and pelvic endometriosis', 'O.P']

answer: @entity530 :: (MESH:D010386,Disease) :: ['pelvic endometriosis']


abstract: @entity1 with @entity661 ( @entity661 ) often present with symptoms similar to those of @entity583 ( @entity583 ). We analyzed blood concentrations of mediators of @entity32 and platelet- and monocyte-activity markers in @entity1 with @entity661 and @entity583 for significant differences. Clinical data of @entity1 with @entity661 (n = 16) and acute @entity583 (n = 16) were obtained. Serial blood samples were taken at the time of hospital admission (t(0)), after 2-4 days (t(1)) and after 4-7 weeks (t(2)), respectively. Plasma concentrations of @entity650 , @entity6977 , soluble @entity2936 ligand (sCD40L), and @entity2842 ( @entity2842 ) were determined with an ELISA. Tissue factor binding on monocytes, platelet-activation marker @entity8729 , platelet @entity11603 ( @entity11603 ), and platelet-monocyte aggregates were measured using flow cytometry. Expression of @entity8729 on platelets and @entity650 plasma levels were significantly lower in @entity1 with @entity661 compared to @entity583 at the time of hospital admission. @entity6977 plasma levels were significantly elevated in @entity1 with @entity661 compared to @entity1 with @entity583 at 2-4 days after hospital admission. No significant differences were observed concerning sCD40L and @entity2842 plasma levels, tissue factor binding on monocytes, @entity11603 expression on platelets, and platelet-monocyte aggregates at any point in time. Our results indicate that inflammatory mediators and platelet-activity markers contribute to the differences in the pathogenesis of @entity583 and @entity661 .

title: Platelet and monocyte activity markers and mediators of @entity32 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2842 :: ('6347', 'Gene') :: ['MCP-1', 'monocyte chemotactic protein 1']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['TC', 'Takotsubo cardiomyopathy']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

answer: @entity661 :: (MESH:D054549,Disease) :: ['Takotsubo cardiomyopathy']


abstract: @entity1 with @entity661 ( @entity661 ) often present with symptoms similar to those of @entity583 ( @entity583 ). We analyzed blood concentrations of mediators of @entity32 and platelet- and monocyte-activity markers in @entity1 with @entity661 and @entity583 for significant differences. Clinical data of @entity1 with @entity661 (n = 16) and acute @entity583 (n = 16) were obtained. Serial blood samples were taken at the time of hospital admission (t(0)), after 2-4 days (t(1)) and after 4-7 weeks (t(2)), respectively. Plasma concentrations of @entity650 , @entity6977 , soluble @entity2936 ligand (sCD40L), and @entity2842 ( @entity2842 ) were determined with an ELISA. Tissue factor binding on monocytes, platelet-activation marker @entity8729 , platelet @entity11603 ( @entity11603 ), and platelet-monocyte aggregates were measured using flow cytometry. Expression of @entity8729 on platelets and @entity650 plasma levels were significantly lower in @entity1 with @entity661 compared to @entity583 at the time of hospital admission. @entity6977 plasma levels were significantly elevated in @entity1 with @entity661 compared to @entity1 with @entity583 at 2-4 days after hospital admission. No significant differences were observed concerning sCD40L and @entity2842 plasma levels, tissue factor binding on monocytes, @entity11603 expression on platelets, and platelet-monocyte aggregates at any point in time. Our results indicate that inflammatory mediators and platelet-activity markers contribute to the differences in the pathogenesis of @entity583 and @entity661 .

title: Platelet and monocyte activity markers and mediators of XXXX in @entity661 .

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']


abstract: @entity12751 ( @entity12751 ) is a progressive @entity66 caused by @entity12751 . First choice of treatment in @entity12751 @entity1 is @entity8 ( @entity8 ). The effect of @entity8 has been shown to have limited influence on skeletal manifestations by poor penetration of musculoskeletal tissues by the enzyme derived from donor leucocytes. Aim of this study was to investigate the effect of @entity8 on the craniocervical junction (CCJ) in @entity12751 @entity1 . We analysed retrospectively sequential magnetic resonance imaging (MRI) scans of 30 @entity1 with @entity12751 treated by @entity8 since 1982 at the Royal Manchester @entity1 's Hospital, UK, in order to determine whether the @entity1 suffer from @entity24179 . Results were compared with biochemical and clinical characteristics: Enzyme activity (EA), chimerism, urinary glycosaminoglycan (GAG) excretion and neurological status. Investigations were part of standard clinical procedures. Results are descriptive in presentation. In 26/30 @entity1 a @entity204 was feasible. The majority showed a normal dens length and an increase with age. Only 3/26 revealed a @entity24179 . One of them had only partial donor engraftment (DE) with reduced EA, one of them suffered from @entity2132 ( @entity2132 ). One @entity1 with only partial DE and reduced EA presented with @entity1613 until preadolescence but normalized later on. There may be a trend towards lower EA and the occurrence of DH in transplanted @entity5684 @entity1 - perhaps the dosage of enzyme plays a role in the correction of skeletal complications in this @entity1 group. @entity8 @entity1 with incomplete DE and therefore lower EAs may require special attention and care.

title: The craniocervical junction following successful XXXX for @entity12751 ( @entity12751 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children', 'patient']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['HSCT', 'haematopoietic stem cell transplantation']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['multisystemic disorder']

entities_list: @entity24179 :: ('MESH:D003719', 'Disease') :: ['dens hypoplasia']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'chronic graft versus host disease']

entities_list: @entity12751 :: ('MESH:D008059', 'Disease') :: ['Mucopolysaccharidosis I Hurler', 'Hurler', 'Hurler disease', 'alpha-L-iduronidase deficiency', 'MPS IH']

entities_list: @entity1613 :: ('MESH:D011230', 'Disease') :: ['initial dens hypoplasia']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['determination of odontoid hypoplasia']

answer: @entity8 :: (MESH:D007674,Disease) :: ['haematopoietic stem cell transplantation']


abstract: @entity12751 ( @entity12751 ) is a progressive @entity66 caused by @entity12751 . First choice of treatment in @entity12751 @entity1 is @entity8 ( @entity8 ). The effect of @entity8 has been shown to have limited influence on skeletal manifestations by poor penetration of musculoskeletal tissues by the enzyme derived from donor leucocytes. Aim of this study was to investigate the effect of @entity8 on the craniocervical junction (CCJ) in @entity12751 @entity1 . We analysed retrospectively sequential magnetic resonance imaging (MRI) scans of 30 @entity1 with @entity12751 treated by @entity8 since 1982 at the Royal Manchester @entity1 's Hospital, UK, in order to determine whether the @entity1 suffer from @entity24179 . Results were compared with biochemical and clinical characteristics: Enzyme activity (EA), chimerism, urinary glycosaminoglycan (GAG) excretion and neurological status. Investigations were part of standard clinical procedures. Results are descriptive in presentation. In 26/30 @entity1 a @entity204 was feasible. The majority showed a normal dens length and an increase with age. Only 3/26 revealed a @entity24179 . One of them had only partial donor engraftment (DE) with reduced EA, one of them suffered from @entity2132 ( @entity2132 ). One @entity1 with only partial DE and reduced EA presented with @entity1613 until preadolescence but normalized later on. There may be a trend towards lower EA and the occurrence of DH in transplanted @entity5684 @entity1 - perhaps the dosage of enzyme plays a role in the correction of skeletal complications in this @entity1 group. @entity8 @entity1 with incomplete DE and therefore lower EAs may require special attention and care.

title: The craniocervical junction following successful @entity8 for XXXX ( @entity12751 ).

answer: @entity12751 :: (MESH:D008059,Disease) :: ['mucopolysaccharidosis type I H']


abstract: @entity12751 ( @entity12751 ) is a progressive @entity66 caused by @entity12751 . First choice of treatment in @entity12751 @entity1 is @entity8 ( @entity8 ). The effect of @entity8 has been shown to have limited influence on skeletal manifestations by poor penetration of musculoskeletal tissues by the enzyme derived from donor leucocytes. Aim of this study was to investigate the effect of @entity8 on the craniocervical junction (CCJ) in @entity12751 @entity1 . We analysed retrospectively sequential magnetic resonance imaging (MRI) scans of 30 @entity1 with @entity12751 treated by @entity8 since 1982 at the Royal Manchester @entity1 's Hospital, UK, in order to determine whether the @entity1 suffer from @entity24179 . Results were compared with biochemical and clinical characteristics: Enzyme activity (EA), chimerism, urinary glycosaminoglycan (GAG) excretion and neurological status. Investigations were part of standard clinical procedures. Results are descriptive in presentation. In 26/30 @entity1 a @entity204 was feasible. The majority showed a normal dens length and an increase with age. Only 3/26 revealed a @entity24179 . One of them had only partial donor engraftment (DE) with reduced EA, one of them suffered from @entity2132 ( @entity2132 ). One @entity1 with only partial DE and reduced EA presented with @entity1613 until preadolescence but normalized later on. There may be a trend towards lower EA and the occurrence of DH in transplanted @entity5684 @entity1 - perhaps the dosage of enzyme plays a role in the correction of skeletal complications in this @entity1 group. @entity8 @entity1 with incomplete DE and therefore lower EAs may require special attention and care.

title: The craniocervical junction following successful @entity8 for @entity12751 ( XXXX ).

answer: @entity12751 :: (MESH:D008059,Disease) :: ['Hurler syndrome']


abstract: @entity1457 proteins (HSPs) are among the most highly conserved and immunogenic proteins shared by microbial agents and mammals. @entity1 (h) @entity11217 is upregulated under stress conditions and serves as a target for cross-reactive cytotoxic HSP-serum-antibodies. The present study evaluates the expressions of @entity11217 and its homologue chlamydial (c) @entity11217 in advanced @entity1 @entity301 and correlates intimal tissue-bound HSP expressions with circulating HSP-antibodies. Coronary atherectomy specimens retrieved from 100 primary target lesions of @entity1 with @entity1459 ( @entity1459 ; n  =  40) or @entity5749 ( @entity5749 ; n  =  60) were assessed immunohistochemically for the presence of @entity11217 and cHSP60. In a subgroup (n  =  40), blood samples were tested for anti-Chl. pn.-IgG/IgA-titers and anti- @entity11217 -antibody titers. Coronary plaques revealed immunoreactive @entity11217 in 55% and cHSP60 in 45% of the lesions. Expression of both HSP homologues was significantly (each p  <  0.001) higher in @entity1459 lesions compared with @entity5749 lesions (7.4 vs. 1.2% and 6.0 vs. 1.1%). HSP homologues showed positive correlations both in @entity1459 - and @entity5749 -lesions (r  =  0.41, 0.33; p  <  0.05). cHSP60 showed no association with anti-Chl. pn.-IgG/IgA-titers, whereas expressions of both homologues correlated positive with anti- @entity11217 -Ab titers (r  =  0.42, p  <  0.05; r  =  0.50, p  <  0.01). Intimal amounts of @entity11217 homologues were associated with increased expressions of @entity1851 , @entity2939 . @entity1 and chlamydial @entity11217 colocalize within @entity301 , most prevalent in lesions associated with @entity1459 . Our data demonstrate a significant correlation between the intimal expressions of @entity11217 homologues and serum @entity11217 antibodies, thereby suggesting that humoral immune reactions may play an important role in @entity453 and plaque instability.

title: Prevalence of intimal XXXX protein 60 homologues in @entity1459 and correlation with anti- @entity1457 protein antibody titers.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients', 'Human']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary lesions', 'coronary atheroma']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['Heat shock']

entities_list: @entity5749 :: ('MESH:D060050', 'Disease') :: ['stable angina', 'SA']

entities_list: @entity1459 :: ('MESH:D000789', 'Disease') :: ['UA', 'unstable angina']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary atherosclerosis']

entities_list: @entity2939 :: ('7099', 'Gene') :: ['Toll-like receptor-4 and tissue factor']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity1457 :: (MESH:D012769,Disease) :: ['heat shock']


abstract: @entity1457 proteins (HSPs) are among the most highly conserved and immunogenic proteins shared by microbial agents and mammals. @entity1 (h) @entity11217 is upregulated under stress conditions and serves as a target for cross-reactive cytotoxic HSP-serum-antibodies. The present study evaluates the expressions of @entity11217 and its homologue chlamydial (c) @entity11217 in advanced @entity1 @entity301 and correlates intimal tissue-bound HSP expressions with circulating HSP-antibodies. Coronary atherectomy specimens retrieved from 100 primary target lesions of @entity1 with @entity1459 ( @entity1459 ; n  =  40) or @entity5749 ( @entity5749 ; n  =  60) were assessed immunohistochemically for the presence of @entity11217 and cHSP60. In a subgroup (n  =  40), blood samples were tested for anti-Chl. pn.-IgG/IgA-titers and anti- @entity11217 -antibody titers. Coronary plaques revealed immunoreactive @entity11217 in 55% and cHSP60 in 45% of the lesions. Expression of both HSP homologues was significantly (each p  <  0.001) higher in @entity1459 lesions compared with @entity5749 lesions (7.4 vs. 1.2% and 6.0 vs. 1.1%). HSP homologues showed positive correlations both in @entity1459 - and @entity5749 -lesions (r  =  0.41, 0.33; p  <  0.05). cHSP60 showed no association with anti-Chl. pn.-IgG/IgA-titers, whereas expressions of both homologues correlated positive with anti- @entity11217 -Ab titers (r  =  0.42, p  <  0.05; r  =  0.50, p  <  0.01). Intimal amounts of @entity11217 homologues were associated with increased expressions of @entity1851 , @entity2939 . @entity1 and chlamydial @entity11217 colocalize within @entity301 , most prevalent in lesions associated with @entity1459 . Our data demonstrate a significant correlation between the intimal expressions of @entity11217 homologues and serum @entity11217 antibodies, thereby suggesting that humoral immune reactions may play an important role in @entity453 and plaque instability.

title: Prevalence of intimal @entity1457 protein 60 homologues in @entity1459 and correlation with anti- XXXX protein antibody titers.

answer: @entity1457 :: (MESH:D012769,Disease) :: ['heat shock']


abstract: @entity1457 proteins (HSPs) are among the most highly conserved and immunogenic proteins shared by microbial agents and mammals. @entity1 (h) @entity11217 is upregulated under stress conditions and serves as a target for cross-reactive cytotoxic HSP-serum-antibodies. The present study evaluates the expressions of @entity11217 and its homologue chlamydial (c) @entity11217 in advanced @entity1 @entity301 and correlates intimal tissue-bound HSP expressions with circulating HSP-antibodies. Coronary atherectomy specimens retrieved from 100 primary target lesions of @entity1 with @entity1459 ( @entity1459 ; n  =  40) or @entity5749 ( @entity5749 ; n  =  60) were assessed immunohistochemically for the presence of @entity11217 and cHSP60. In a subgroup (n  =  40), blood samples were tested for anti-Chl. pn.-IgG/IgA-titers and anti- @entity11217 -antibody titers. Coronary plaques revealed immunoreactive @entity11217 in 55% and cHSP60 in 45% of the lesions. Expression of both HSP homologues was significantly (each p  <  0.001) higher in @entity1459 lesions compared with @entity5749 lesions (7.4 vs. 1.2% and 6.0 vs. 1.1%). HSP homologues showed positive correlations both in @entity1459 - and @entity5749 -lesions (r  =  0.41, 0.33; p  <  0.05). cHSP60 showed no association with anti-Chl. pn.-IgG/IgA-titers, whereas expressions of both homologues correlated positive with anti- @entity11217 -Ab titers (r  =  0.42, p  <  0.05; r  =  0.50, p  <  0.01). Intimal amounts of @entity11217 homologues were associated with increased expressions of @entity1851 , @entity2939 . @entity1 and chlamydial @entity11217 colocalize within @entity301 , most prevalent in lesions associated with @entity1459 . Our data demonstrate a significant correlation between the intimal expressions of @entity11217 homologues and serum @entity11217 antibodies, thereby suggesting that humoral immune reactions may play an important role in @entity453 and plaque instability.

title: Prevalence of intimal @entity1457 protein 60 homologues in XXXX and correlation with anti- @entity1457 protein antibody titers.

answer: @entity1459 :: (MESH:D000789,Disease) :: ['unstable angina']


abstract: BACKGROUND: Neonatal @entity4008 remains a severe @entity166 with mortality rates varying between 10% and 15%. The clinical and bacteriologic features of @entity693 collected from January 2001 to December 2007 in a French national survey are presented here. METHODS: Cases of @entity693 were prospectively collected by a network of 252 pediatric wards covering 61% of French pediatric wards, associated with 168 microbiology laboratories. @entity693 was classified as early-onset (d0-d4) and late-onset (d5-d28). Statistical analyses were performed according to gestational age and weight at birth. RESULTS: A total of 444 cases of neonatal @entity4008 were reported by 114 pediatric wards. Five cases were excluded from analysis. @entity1892 ( @entity1892 ) and @entity526 accounted respectively for 59% and 28% of the cases, followed by Gram-negative bacilli other than @entity526 (4%), other streptococci (4%), @entity3631 (3%), and @entity5125 (1.5%). @entity1892 was the most common pathogen both in early-onset (77% vs. 18% for @entity526 ) and in late-onset @entity693 (50% vs. 33% for @entity526 ). Among preterm @entity1 , @entity526 was more commonly isolated (45% vs. 32% for @entity1892 ), especially in very preterm @entity1 (54%). @entity1892 was more often involved in @entity410 than @entity526 (41% vs. 25%). The overall mortality rate was 13% but reached 25% in preterm or small for gestational age @entity1 , regardless of the etiology. CONCLUSIONS: @entity1892 was the dominant cause of neonatal @entity4008 , with 77% of early-onset and 50% of late-onset cases. @entity526 was the most common bacteria in preterm @entity1 .

title: Neonatal XXXX : 444 Cases in 7 Years.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity4008 :: ('MESH:D016920', 'Disease') :: ['bacterial meningitis']

entities_list: @entity5125 :: ('1639', 'Species') :: ['Listeria monocytogenes']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['Neonatal meningitis', 'neonatal meningitis', 'meningitis']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['Group B streptococci', 'GBS']

entities_list: @entity3631 :: ('487', 'Species') :: ['Neisseria meningitidis']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious disease']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity4008 :: (MESH:D016920,Disease) :: ['Bacterial Meningitis']


abstract: PURPOSE: The aim of research study was to evaluate the effect of corneal cross-linking (CXL) in the frame of @entity1 with progressive @entity9042 1 year after treatment. METHODS: There were 40 eyes of 35 @entity1 with mean age 28, 45 +/- 9.3 (SD) (15 to 48 years) included in the study. @entity1 were treated with standard protocol of CXL with abrasion of corneal epithelium. Complete ophthalmological examination included best corrected spectacles visual acuity (BCSVA), slit-lamp microscopic finding, corneal topography and corneal thickness measured with ultrasound method was performed before, on the 5-th day, 1. 6., 12. month after CXL. We divided @entity1 according to the stage of @entity9042 into 2 groups (stage I. and stage II.) and according to the age into 3 groups (until 20, from 21 to 39, over 40 years). RESULTS: In all treated eyes, the CXL was without relevant complications. The only complication was stromal haze of @entity267 . In the evaluation based on stage of @entity9042 , in the first group any @entity1 became a haze of @entity267 in 1 year after CXL. In the second group 35.7% of @entity1 had a haze of @entity267 . The average BCSVA 1 year after treatment was improved in the 1. group about 5.38 letter and in the 2. group about 1.25 letter. Topographic analysis showed decrease of simulated keratometry and refraction (1. group--0.1 D, 2. group--0.17 D), maximal keratometry and refraction (1. group--0.67 D, 2. group--0.76 D). Minimal keratometry and refraction in the 1. group decreased (1.17 D) and increased in the 2. group (1.09 D). In the evaluation based on the age was haze monitored in the first group one year after CXL in 12.5% of @entity735 . In the second group was haze of @entity267 in 20% of eyes and in the third group consisting of @entity1 over 40 years old, in 50% of eyes. The average BCSVA was improved in the 1. group (2.85 letter), and in the 2. group (3.68 letter).The average BCSVA was decreased in the oldest @entity1 in about 1.43 letter. In the 1. and 2. group the topographic analysis showed decrease of simulated keratometry and refraction (1. group--0.12D, 2. group--0.21D), maximal keratometry and refraction (1. group--1.13 D, 2. group--0,68D), minimal keratometry and refraction (1. group--1.17D, 2. group--0,69 D). In the 3. group the topography analysis showed increase of simulated keratometry and refraction (0,8D), maximal keratometry and refraction (0,98D), minimal keratometry and refraction (0,28D). Corneal pachymetry remained stable in all researched groups of @entity1 . CONCLUSIONS: CXL is considered as safe procedure to stop progression of @entity9042 also for @entity1 until 19 years old. The best effect and minimal complications were by @entity1 until 40 years old and by @entity1 with the I. grade.

title: [Corneal cross-linking--modern method of XXXX treatment].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['researched eyes']

entities_list: @entity9042 :: ('MESH:D007640', 'Disease') :: ['keratoconus']

answer: @entity9042 :: (MESH:D007640,Disease) :: ['keratoconus']